• Blog
  • Glaucoma Treatment Market Report

    Glaucoma Treatment Market Report

    Glaucoma Treatment Market Report
    Report code - SRHL292 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Glaucoma Treatment Market, Dynamics, and Market Analysis
    See more...

    Impact of COVID-19 on Glaucoma Treatment Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Glaucoma Treatment Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Glaucoma Treatment Market is projected to grow from USD xx million in 2020 to USD xx million by 2026 at a CAGR of over 7.4% during the forecast period.

    Figure: Global Glaucoma Treatment Market Size, 2020-2026 (USD Million)

    Glaucoma-Treatment-Market-Forecast

    Wish to get a free sample? Register Here

    What is Glaucoma?

    Glaucoma is primarily referred to as a silent thief of sight, as most of its types typically exhibit no symptoms, no pain until noticeable vision loss occurs. It is a group of related eye disorders which occurs mainly due to damage to the optic nerve which carries information from the eye to the brain. In most cases, associated with ocular hypertension, a condition when the pressure inside the eye is higher than normal pressure but sometimes it can occur when the intraocular pressure is normal.

    Key Players

    Key players operating in the global glaucoma treatment market are-

    • Merck & Co., Inc. (The U.S),
    • Novartis AG (Switzerland), Allergan Plc (The U.S),
    • AERIE PHARMACEUTICALS, INC. (The U.S),
    • Bausch & Lomb Incorporated (The U.S),
    • Akorn, Incorporated (The U.S),
    • Pfizer Inc (The U.S),
    • Inotek Pharmaceuticals (The U.S), and
    • Santen Pharmaceutical Co., Ltd.(Japan).

    Market Dynamics

    Rising cases of glaucoma are a key factor boosting the demand for glaucoma treatment across the globe.

    • As glaucoma is a painless disorder of the eye that does not exhibit any kind of symptoms until significant vision loss, thus several patients suffering from glaucoma are rising day by day.
    • In addition, rising awareness of glaucoma by pharmaceutical and government companies’ campaigns are further creating lucrative growth opportunities for the market players.
    • Furthermore, significant technological developments in treatment as eye drop are the primary control sage for glaucoma, and various pharmaceutical and biotechnological companies are investing in new product development for glaucoma is another reason behind the market growth.

    Segment Analysis

    Drug Class Trends

    Based on drug class, the global glaucoma treatment market has been categorized into prostaglandin analogs, beta-blockers, alpha agonists, carbonic anhydrase inhibitors, others.

    • Among these, the prostaglandin analogs segment garnered the highest market share in 2020 and is likely to register a healthy CAGR during the review period.
    • This is mainly attributed to the growing number of geriatric patients with glaucoma and prostaglandin analogs are administered as an eye drop, thus ease of using the drug is likely to augment the growth of prostaglandin analogs.

    Regional Trends

    By region, the North American market witnessed the highest market share in 2020 and is projected to grow at a robust CAGR during the review period.

    • This can be attributed to rising healthcare expenditure, the presence of major healthcare companies, and the increasing senior population, promulgate the product region in the region.
    • Moreover, growing cases of glaucoma in the region coupled with better healthcare infrastructure further boost the regional growth.

    COVID-19 Impact on Global Glaucoma Treatment Market

    The ongoing COVID-19 pandemic has significantly affected the glaucoma treatment industry due to the shift of medical treatment from glaucoma and other health condition towards the treatment of coronavirus-affected patients. Many government healthcare facilities have recognized glaucoma as an elective. Thus, all the surgeries associated with this condition were postponed or canceled across the globe due to the outbreak of the COVID-19 pandemic.

    Critical Questions Answered in the Report

    • What are the key trends in the global glaucoma treatment market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global glaucoma treatment market?
    • What are the key strategies adopted by the major vendors to lead in the global glaucoma treatment market?
    • What is the market share of the top vendors?

    Want to know the full scope of the report? Register Here

    Target Audience

    The following is a list of the customers that the Glaucoma Treatment market aims to convert the most:

    • Glaucoma treatment companies
    • Hospitals
    • Diagnostic centers and laboratories
    • Academic Institutions
    • Research centers & organizations

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The glaucoma treatment market is expected to witness an impressive growth of 7.4% CAGR in the foreseeable future.

    Merck & Co., Inc. (The U.S), Novartis AG (Switzerland), Allergan Plc (The U.S), AERIE PHARMACEUTICALS, INC. (The U.S), Bausch & Lomb Incorporated (The U.S), Akorn, Incorporated (The U.S), Pfizer Inc (The U.S), Inotek Pharmaceuticals (The U.S) and Santen Pharmaceutical Co., Ltd.(Japan) are among the key players in glaucoma treatment market.

    North America witnessed the largest share in the glaucoma treatment market in 2020.

    Rising cases of glaucoma, rising awareness of glaucoma by pharmaceutical and government companies campaigns, significant technological developments are the factors driving the growth of glaucoma treatment market.

    The prostaglandin analogs segment is expected to register a healthy CAGR in the glaucoma treatment market during the forecast period.

    Glaucoma treatment companies, Hospitals, Diagnostic centers and laboratories, Academic Institutions, Research centers & organizations are the glaucoma treatment market.

    •